Parexel debuts its Patient Innovation Center aiming for improved biopharma development

Patients in a hospital waiting room
Parexel’s patient-centric approach and new innovation center target all areas of biopharma development from clinical trial design, recruitment, execution and market access. (Getty/SuwanPhoto)

Global CRO Parexel debuted its Patient Innovation Center that is designed to boost efficiency and success across the board for biopharmaceutical development.

Parexel’s patient-centric approach and new innovation center target all areas of biopharma development from clinical trial design, recruitment, execution and market access, the company said. Parexel’s push is supported by a recent report it commissioned from The Economist Intelligence Unit that said patient-centric trials resulted in recruiting participant patients in half the time, and that drugs developed using such an approach were 19% more likely to be launched. Despite this, the report said, a patient-centric approach was used in only 5.2% of phase 2 and 3 trials across the industry.

“While the evidence is clear that patient-centric approaches can improve the development process, many sponsors remain in need of a road map to effectively apply these strategies over time,” Sy Pretorius, M.D., a senior VP at Parexel, said in a statement. “Through the Patient Innovation Center, we aim to bring the full breadth of our services, expertise and innovation to clients to help more-effectively implement these approaches, reducing the barriers and optimizing patient involvement throughout the drug development and commercialization journey.”

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

A little over a year ago, Parexel merged into Pamplona Capital Management in a $5 billion deal that saw the CRO go private. In March, company co-founder Josef von Rickenbach, who was the chairman and chief executive, retired after a 35-year tenure. Jamie Macdonald, who previously led INC Research, was tapped as von Rickenbach’s replacement.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

PPD, which is going public (again) after years of being private, is ramping up its clinical research units (CRUs).

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.